ALNYLAM PHARMACEUTICALS, INC. - 8-K Filing

Alnylam Pharmaceuticals authorizes $1.0 billion stock repurchase program and announces departure of Chief Commercialization Officer.

SEC EDGAR ·

Tickers: $ALNY

Read the full article at SEC EDGAR

More Regulatory news